Menu
← Oncology Approval Tracker
FDA DECISION ·
Pluvicto
lutetium Lu 177 vipivotide tetraxetan · Advanced Accelerator Applications / Novartis
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with PSMA-positive metastatic castration-resistant prostate cancer previously treated with an androgen receptor pathway inhibitor and taxane chemotherapy.
LAMPGEN ANALYSIS
Why it matters
The original approval links PSMA-directed radioligand therapy to a positive imaging result and two prior treatment classes.
What research teams should watch
Coordinate PSMA imaging, nuclear medicine referral, treatment delivery, and radiation-safety counseling.
PRIMARY RECORDS